SCHEMBL22999965

SCHEMBL22999965

CCOC(=O)C1C(=O)CCN(C2CCN(C(=O)OC(C)(C)C)[C@H](C)C2)C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 3/20 0.34
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
ATM Q13315 2/20 0.32
FPR2 P25090 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23000018 0.85 TP53 (0.47) MEN1KMT2AALDH1A1TSHRTP53
SCHEMBL22999540 0.81 FPR2 (0.42) MEN1KMT2AALDH1A1TSHRTP53
SCHEMBL20476316 0.79 MAPT (0.40) MEN1KMT2AALDH1A1TSHRGPR119
SCHEMBL22323003 0.78 ALDH1A1 (0.40) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL16530356 0.76 ALDH1A1 (0.49) MEN1KMT2AALDH1A1TSHRKDM4E
SCHEMBL23021084 0.76 GPR119 (0.38) TP53GPR119ATMKDM4EHSD17B10
SCHEMBL22216157 0.76 POLB (0.41) MEN1KMT2AALDH1A1TSHRKDM4E
SCHEMBL22216375 0.76 POLB (0.44) MEN1KMT2AALDH1A1TSHRHPGD
SCHEMBL3286134 0.75 POLB (0.43) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL28000905 0.74 NFKB1 (0.38) MEN1KMT2AALDH1A1TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021032323-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES GALAPAGOS NV (BE) 2021-02-25 WO disclosed
WO-2021032323-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES GALAPAGOS NV (BE) 2021-02-25 WO disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed